<DOC>
	<DOCNO>NCT02879669</DOCNO>
	<brief_summary>The trial open-label , parallel group , multicentre trial recruit total 30 patient malignant pleural mesothelioma . The trial conduct 2 phase : non-randomised safety phase randomise phase . The safety phase consist lead-in cohort 6 patient treat ONCOS 102 pemetrexed/cisplatin . The randomised phase commence DSMB deem safety lead-in data appropriate continuation . A total 24 patient include randomised phase ; 14 patient randomise receive ONCOS 102 pemetrexed/cisplatin , 10 patient receive pemetrexed/cisplatin alone . The trial 's main objective determination safety , immune activation , clinical response correlation clinical outcome immunological data .</brief_summary>
	<brief_title>A Randomised Phase II Open-label Study With Phase Ib Safety lead-in Cohort ONCOS-102 , Immune-priming GM-CSF Coding Oncolytic Adenovirus , Pemetrexed/Cisplatin Patients With Unresectable Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent . Male female , ≥18 year age . Histologically confirm unresectable ( advanced ) malignant pleural mesothelioma patient candidate curative surgery therapy pemetrexed/cisplatin consider appropriate . This include patient naïve chemotherapy , already receive pemetrexed/cisplatin tumour initially respond , relapse least 6 month . Measurable disease accord Response Evaluation Solid Tumour ( RECIST ) 1.1 . Tumour must accessible intratumoural ( i.t . ) injection tumour core needle biopsy thoracoscopy tissue sample immunohistochemistry analysis . Eastern Cooperative Oncology Group ( ECOG ) /World Health Organization ( WHO ) performance score 0 1 . Acceptable liver , renal , haematological function . All woman childbearing potential must negative urine serum pregnancy test screening patient must agree use barrier contraception ( i.e . condom ) study treatment 2 month last virus treatment 6 month last dose pemetrexed/cisplatin . Receipt oncolytic virus treatment , vaccination vaccine contain live virus within 4 week Day 1 . Use significant immunosuppressive medication , include high dose corticosteroid ( defined equivalent &gt; 10 mg/day prednisone ) within 4 week Day 1 . Patients participate study investigational drug device within 4 week prior Day 1 . Active bacterial , viral , fungal infection , require systemic therapy . Severe arrhythmia , heart failure , previous cardiac infarction , acute inflammatory heart disease . Concomitant disease condition could interfere conduct study , would , opinion Investigator , pose unacceptable risk patient , include study . Known infection HIV , hepatitis B , hepatitis C. Known brain metastasis . History organ transplant . Females pregnant breast feeding . Unwillingness inability comply study protocol reason . Patients preexist hearing loss neuropathy may worsen due potential neurotoxicity cisplatin . Patients history hypersensitivity cisplatin pemetrexed cyclophosphamide ( metabolite ) . Patients take phenytoin prophylactic use . History malignant tumour , unless patient without evidence disease least 3 year , tumour nonmelanoma skin tumour , cervical carcinoma situ , prostatic carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>